To maximize the commercial potential of our technology, Intarcia continues to evaluate new opportunities for novel and proprietary product candidates, with efforts focused around two areas:

  • Evaluation of new applications of our drug delivery technology to develop products for which we can hold exclusive development and commercialization rights; and
  • Exploration of collaborative opportunities with partners to which our formulation and drug delivery technology and expertise can lend enhancement of life-cycle management, product line extension or a competitive edge.

To learn more about Intarcia's partnering opportunities or accessing Intarcia's formulation and delivery technology platform, please contact Intarcia Business Development at


Our Pipeline

Intarcia's lead product candidate, ITCA 650 is being developed for the treatment of type 2 diabetes and employs Intarcia's proprietary technology platform involving a matchstick-size, miniature osmotic pump that is inserted sub-dermally to provide continuous and consistent drug therapy.